BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38040444)

  • 1. Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α.
    Dekempeneer Y; Massa S; Santens F; Navarro L; Berdal M; Lucero MM; Pombo Antunes AR; Lahoutte T; Van Ginderachter JA; Devoogdt N; D'Huyvetter M
    J Nucl Med; 2023 Dec; 64(12):1941-1948. PubMed ID: 38040444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
    Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
    J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
    Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
    Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
    Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
    J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
    Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
    Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of
    Zhao L; Niu B; Fang J; Pang Y; Li S; Xie C; Sun L; Zhang X; Guo Z; Lin Q; Chen H
    J Nucl Med; 2022 Jun; 63(6):862-868. PubMed ID: 34556528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
    Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
    Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
    Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
    Zboralski D; Hoehne A; Bredenbeck A; Schumann A; Nguyen M; Schneider E; Ungewiss J; Paschke M; Haase C; von Hacht JL; Kwan T; Lin KK; Lenore J; Harding TC; Xiao J; Simmons AD; Mohan AM; Beindorff N; Reineke U; Smerling C; Osterkamp F
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3651-3667. PubMed ID: 35608703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [
    Backhaus P; Gierse F; Burg MC; Büther F; Asmus I; Dorten P; Cufe J; Roll W; Neri D; Cazzamalli S; Millul J; Mock J; Galbiati A; Zana A; Schäfers KP; Hermann S; Weckesser M; Tio J; Wagner S; Breyholz HJ; Schäfers M
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1822-1832. PubMed ID: 34957527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
    J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Viitanen R; Virtanen H; Liljenbäck H; Moisio O; Li XG; Nicolini V; Richard M; Klein C; Nayak T; Jalkanen S; Roivainen A
    Front Immunol; 2022; 13():901693. PubMed ID: 35874707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [
    Langer LBN; Hess A; Korkmaz Z; Tillmanns J; Reffert LM; Bankstahl JP; Bengel FM; Thackeray JT; Ross TL
    Theranostics; 2021; 11(16):7755-7766. PubMed ID: 34335962
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
    Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
    Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
    Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
    J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
    Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.